Skane & all.
Thanks for your kind comments. While I hope your right about the $20 after FDA, I'm basing my projections on some other biomeds that recently reached highs prior to FDA approval on much awaited procedures, then dropped 20 to 30%. While none of this is ocular, and SNRS has a large segment of the population as an oyster, this logic will not determine price. Five years from now, $40 to $50 a share sounds reasonable or a split price with the same value, but history suggests that much can happen in 5 years. Bert has played this right, much better than I.
My plan, subject to change, is to reduce my position at a target price of $18. Repurchase at $12-$14, and follow TA very closely from that point on. By the way, I'd be really surprised if we ever see $4.50 again (and depressed).
Regards,
Sylvester |
